Upstream Bio, Inc. (UPB)

US — Healthcare Sector
Peers:

Automate Your Wheel Strategy on UPB

With Tiblio's Option Bot, you can configure your own wheel strategy including UPB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol UPB
  • Rev/Share 0.0506
  • Book/Share 7.6016
  • PB 2.3022
  • Debt/Equity 0.0038
  • CurrentRatio 38.2718
  • ROIC -0.2958

 

  • MktCap 943414990.0
  • FreeCF/Share -2.1301
  • PFCF -8.2368
  • PE -9.0073
  • Debt/Assets 0.0037
  • DivYield 0
  • ROE -0.359

 

  • Rating
  • Score
  • Recommendation
  • P/E Score
  • DCF Score
  • P/B Score
  • D/E Score

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025
UPB
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral

WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced an upcoming presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, UK, on Sunday, June 15, 2025.

Read More
image for news Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025
Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs
UPB
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

– Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in the third quarter of 2025 – – Top-line data from Phase 2 clinical trial of verekitug in patients with severe asthma now expected in the first half of 2026 – – First patient in Phase 2 clinical trial of verekitug in patients with chronic obstructive pulmonary disease to be dosed in mid-2025 – WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe …

Read More
image for news Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs
Upstream Bio to Present at Upcoming March Investor Conferences
UPB
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Upstream Bio's CEO, will present at the following upcoming March investor conferences: TD Cowen 45th Annual Health Care Conference, Boston MA Tuesday, March 4, 2025, 11:50 a.m.

Read More
image for news Upstream Bio to Present at Upcoming March Investor Conferences

About Upstream Bio, Inc. (UPB)

  • IPO Date 2024-10-11
  • Website https://upstreambio.com
  • Industry Biotechnology
  • CEO E. Rand Sutherland M.P.H., MPH
  • Employees 52
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.